GlassScriptPhysician profile
Vonda Calcutt
NPI 1477591162
$367,981.27
in general payments reported to CMS, 2019-2025
30 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127K · 2020: $96K · 2021: $95K · 2022: $25K · 2023: $4,490 · 2024: $7,518 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,688 · Food and Beverage: $5,268 · Consulting Fee: $4,800 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,313 · Travel and Lodging: $2,221 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,687.50 |
| Food and Beverage | $5,267.85 |
| Consulting Fee | $4,800.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,312.50 |
| Travel and Lodging | $2,221.44 |
| Education | $161.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $317,262.07 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $25,085.22 | 2019-2020 | |
| Abbott Laboratories | $18,499.96 | 2020-2025 | Freestyle Libre 3, Freestyle Libre |
| Medtronic, INC. | $1,229.66 | 2022-2025 | Minimed 780g, Intellis Adaptivestim, Ligasure |
| Lilly USA, LLC | $963.23 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Mannkind Corporation | $951.89 | 2019-2020 | |
| Novo Nordisk INC | $606.21 | 2019-2025 | Ozempic, Rybelsus |
| Insulet Corporation | $416.13 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $350.59 | 2022-2025 | |
| Amgen INC. | $312.31 | 2019-2025 | Tepezza, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $308.97 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $307.55 | 2021-2025 | Korlym |
| Dexcom, INC. | $293.72 | 2019-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $208.49 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.58 | 2019-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $154.32 | 2025 | Yorvipath |
| Abbvie INC. | $143.85 | 2019-2024 | Synthroid |
| Horizon Therapeutics Plc | $117.58 | 2023 | Tepezza |
| Beta Bionics, INC. | $107.83 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $83.93 | 2019-2021 | |
| Cequr Corporation | $79.75 | 2022-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $62.81 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $59.39 | 2025 | Isturisa |
| Medtronic Minimed, INC. | $36.59 | 2019-2020 | |
| Valeritas, INC. | $36.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.69 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $29.28 | 2024 | Strensiq |
| Ascensia Diabetes Care US INC. | $14.95 | 2023 | |
| Madrigal Pharmaceuticals | $14.22 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $13.46 | 2025 | Twiist |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vonda Calcutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.